Patient characteristics
. | . | . | . | . | . | . | Baseline . | . | |
|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y . | Sex . | PTL subtype . | No. of previous regimens . | Response to previous therapy* . | Clinical stage . | WBC count, × 109/L . | Lymphocyte count, × 109/L . | |
| 1 | 60 | M | PTLu | 3 | CR (2 mo) | IIIA | 9.6 | 0.9 | |
| 2 | 70 | M | Angio | 1 | PD | IVA | 4.7 | 1.1 | |
| 3 | 61 | F | PTLu | 2 | PD | IVA | 4.6 | 1.0 | |
| 4 | 65 | M | AILD | 1 | PD | IIIB | 3.6 | 1.1 | |
| 5 | 53 | F | AILD | 2 | CR (3 mo) | IVB | 4.7 | 0.2 | |
| 6 | 79 | M | PTLu | 3 | SD | IVA | 6.0 | 1.5 | |
| 7 | 59 | M | PTLu | 1 | PR (1 mo) | IVB | 25.2 | 2.3 | |
| 8 | 57 | M | PTLu | 1 | PR (2 mo) | IVA | 65.0 | 63.7† | |
| 9 | 62 | M | Angio | 2 | PD | IIIA | 17.8 | 0.9 | |
| 10 | 65 | M | PTLu | 3 | PD | IVA | 1.3 | 0.6 | |
| 11 | 57 | M | PTLu | 2 | PR (8 mo) | IVA | 4.6 | 1.0 | |
| 12 | 78 | M | PTLu | 3 | SD | IIIB | 6.6 | 0.8 | |
| 13 | 57 | M | PTLu | 2 | PD | IVA | 6.4 | 0.9 | |
| 14 | 58 | M | PTLu | 4 | PR (3 mo) | IVA | 6.0 | 0.1 | |
. | . | . | . | . | . | . | Baseline . | . | |
|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y . | Sex . | PTL subtype . | No. of previous regimens . | Response to previous therapy* . | Clinical stage . | WBC count, × 109/L . | Lymphocyte count, × 109/L . | |
| 1 | 60 | M | PTLu | 3 | CR (2 mo) | IIIA | 9.6 | 0.9 | |
| 2 | 70 | M | Angio | 1 | PD | IVA | 4.7 | 1.1 | |
| 3 | 61 | F | PTLu | 2 | PD | IVA | 4.6 | 1.0 | |
| 4 | 65 | M | AILD | 1 | PD | IIIB | 3.6 | 1.1 | |
| 5 | 53 | F | AILD | 2 | CR (3 mo) | IVB | 4.7 | 0.2 | |
| 6 | 79 | M | PTLu | 3 | SD | IVA | 6.0 | 1.5 | |
| 7 | 59 | M | PTLu | 1 | PR (1 mo) | IVB | 25.2 | 2.3 | |
| 8 | 57 | M | PTLu | 1 | PR (2 mo) | IVA | 65.0 | 63.7† | |
| 9 | 62 | M | Angio | 2 | PD | IIIA | 17.8 | 0.9 | |
| 10 | 65 | M | PTLu | 3 | PD | IVA | 1.3 | 0.6 | |
| 11 | 57 | M | PTLu | 2 | PR (8 mo) | IVA | 4.6 | 1.0 | |
| 12 | 78 | M | PTLu | 3 | SD | IIIB | 6.6 | 0.8 | |
| 13 | 57 | M | PTLu | 2 | PD | IVA | 6.4 | 0.9 | |
| 14 | 58 | M | PTLu | 4 | PR (3 mo) | IVA | 6.0 | 0.1 | |
WBC indicates white blood cell; M, male; PTLu, peripheral lymphoma unspecified; Angio, angiocentric T-cell lymphoma; F, female; and AILD, angioimmunoblastic lymphoma.
The number in brackets indicates the duration of responce (months) to previous therapy.
Lymphoma cells present in the blood of this patient.